BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $0.11 on Monday. The firm has a market capitalization of $8.74 million, a P/E ratio of -0.50 and a beta of 1.46. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The stock’s 50-day simple moving average is $0.21 and its two-hundred day simple moving average is $0.47. BioLineRx has a twelve month low of $0.08 and a twelve month high of $1.44.

BioLineRx shares are going to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 29th.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. As a group, equities analysts anticipate that BioLineRx will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned about 0.15% of BioLineRx at the end of the most recent quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.